GEN Exclusives

More »

GEN News Highlights

More »
Aug 2, 2011

PhyNexus and BAC Combine Technologies for Small-Volume Protein Purification

  • PhyNexus and BAC are together launching a range of BAC’s CaptureSelect® ligands in PhyNexus’ PhyTip® column format. They are designed for parallel processing in an automated format.

    The columns can be used with any of the manufacturer’s robotic liquid-handling platforms. Pure and highly concentrated samples obtained from the processing are ready for cell-based assays, analytics, or any desired functional test.

    In addition, PhyTip columns set up a matrix of purification conditions. This allows researchers to scout for the best purification conditions, resulting in high yield and activity.

    “BAC has created a unique and powerful platform for affinity purification with its range of CaptureSelect products,” comments Douglas Gjerde, Ph.D., CEO of PhyNexus, adding: “The availability of the CaptureSelect resins in the PhyTip column format provides additional flexibility to scientists who wish to determine the best purification conditions for their needs.”

    BAC CaptureSelect products are affinity ligands created by a technology based on Camelid-derived single domain antibody fragments. The ligand is a 12 kD single domain fragment which comprises the 3 CDRs that form the antigen binding domain, efficiently produced by the yeast Saccharomyces cerevisiae.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?